Optimal frequency of changing intravenous administration sets: Is it safe to prolong use beyond 72 hours?

Infection Control and Hospital Epidemiology

Volumn 22, Issue 3, 2001, Pages 136-139

  Raad, Issam ^a   Hanna, Hend A ^a   Awad, Awad ^b   Alrahwan, Amin ^c   Bivins, Carol ^a   Khan, Asma ^a   Richardson, Deborah ^a   Umphrey, Jan L ^a   Whimbey, Estella ^a   Mansour, Georganne ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b St Joseph's Paterson Medical Center   (United States)

^c The University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BLOOD TRANSFUSION; CANCER PATIENT; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; INFUSION; INTRAVENOUS ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PARENTERAL NUTRITION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; TUBE;

EID: 0035079639     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/501879     Document Type: Article

References (16)

1. Guideline for prevention of intravascular device-related infections
2. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial
3. Nationwide epidemic of septicemia caused by contaminated intravenous products
4. Nosocomial bacteremia associated with intravenous fluid therapy
5. Contamination of intravenous fluid: Effects of changing administration sets
6. Safety of changing intravenous delivery systems at longer than 24-hour intervals
7. Intravenous tubing with burettes can be safely changed at 48-hour intervals
8. Intravenous tubing containing burettes can be safely changed at 72-hour intervals
9. Prospective study of replacing administration sets for intravenous therapy at 48- vs 72-hour intervals. 72 hours is safe and cost-effective
10. The relationship between intravenous fluid contamination and the frequency of tubing replacement
11. Nosocomial sepsis associated with interleukin-2
12. Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses
13. Association of interleukin-2 therapy with staphylococcal bacteremia
14. Bacterial infections in lymphoma patients treated with recombinant interleukin-2
15. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2
16. A randomized trial of 72- versus 24-hour intravenous tubing set changes in newborns receiving lipid therapy